I disagree with you on this one. Neuren made an excellent deal.
"The two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits." <- Neuren has the ROW rights for Trof which equals more income than the 60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales
I personally think Acadia learned its lesson from the deal they made with NEU and secure them more rights in future deals which they have achieved. Plus they have secured a 2nd compound (the undisclosed one), which again they didnt do with Neuren. Otherwise they would have aimed at NZZ 2591 already.
my opinion only ...
ACADIA PARTNERSHIP STOKE THERAPEUTICS, page-8
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B | |||
| Open | High | Low | Value | Volume |
| $15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1498 | $15.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 8296 | 2 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |